glp-1compoundpharmacy

The formulation archive
Independent editorial information · not individual medical advice

Commercial pages may contain paid referral links. Compare the full payment terms and licensed-care details before enrollment.

This page contains affiliate links. We may earn a commission if you sign up through them, at no cost to you. All recommendations are independent.

When Your Compounder Switches API Suppliers: The Signals You Should Ask About

The active ingredient in your compounded semaglutide doesn't come from thin air. It comes from a specific API manufacturer, typically in China or India, and passes through import controls, testing, and pharmacy receiving before it becomes a vial in your fridge. Sometimes pharmacies switch suppliers. Here's what to watch for.

Why Pharmacies Switch

API supplier switches happen for a few reasons: better pricing, better lead times, cleaner test results at the new supplier, supply disruption at the old one, or regulatory issues that make the old supplier unusable. None of these are inherently good or bad — a switch to a better supplier is a win, a switch to a cheaper-but-lower-quality supplier is a loss. The question is how you tell the difference.

The Signals

You may notice several things after a supplier switch, even without being told. Product appearance can shift subtly — very slight color differences in reconstituted solution, or slightly different lyophilized cake appearance for vials that shipped dry. Injection site reaction patterns may change (more or less redness, more or less burning sensation). Subjective effect may feel different, especially for the first few doses on a new lot. Batch numbers on your vial will change (they always do, but a supplier switch may correlate with a broader numbering change).

None of these signals independently prove a supplier change. All of them together over the course of a refill are a reasonable basis to ask.

Embody

Injectable semaglutide — pricing varies

Injectable semaglutide only; a lead compounded-injectable option.

  • Injectable semaglutide focus
  • Standard 12-week titration
  • Direct-to-patient pharmacy shipping
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →
Sponsored partner · Weight-management telehealthGala GLP-1

Review program enrollment, whether medication is compounded, dispensing pharmacy information, and the total ongoing price.

Explore Gala GLP-1 ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.

Questions to Ask

Reasonable questions to send to your compounder or its patient care team: "Has the API supplier for your semaglutide changed in the past three months?" "Do you have a current Certificate of Analysis for the batch shipped in my most recent order?" "Is the API manufactured under DMF-supported conditions?" "What third-party testing do you perform on incoming API?"

Reasonable pharmacies answer these questions directly. Pharmacies that decline to answer, refuse CoAs, or respond with "proprietary information" language should be treated as opaque — you're within your rights as a patient to know the basis of a compounded product you're injecting.

Sponsored partner · Weight-management telehealthOak GLP-1

Review current treatment pathways, screening and follow-up, and clarify which medication and monthly charges apply.

Explore Oak GLP-1 ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.
SPONSORED CARE OPTION

Sesame

Compare licensed-clinician services and ask about pharmacy sourcing, FDA-approved treatment options and itemized charges. Compounded medicines are not FDA-approved.

Pricing, medication access, service area and plan terms must be confirmed with the provider. This is not a drug-specific checkout link.

Explore Sesame program ↗

What a Good Response Looks Like

A good response confirms whether a switch occurred, explains why (better quality, better lead time, cost stability), and offers current testing documentation. Some pharmacies proactively notify patients of supplier changes and share testing data with the notification — that's best-in-class behavior.

MadeMed

Oral tirzepatide ~$229/mo

Independent compounder offering compounded oral tirzepatide.

  • Compounded oral tirzepatide
  • $167–$229 range per dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

When to Consider Switching Pharmacies

Not every supplier switch warrants leaving a pharmacy. But a switch combined with declining transparency, or a switch that visibly affects product quality in ways the pharmacy dismisses, is a reasonable basis to line up an alternative. Keep in mind you don't have to switch immediately — you can complete your current supply, evaluate the new-lot experience, and make an informed decision at the next refill point.

SHED

Starts lower, $399/mo at 7.5mg+

Note: SHED's price jumps to $399/mo once you titrate to 7.5mg or higher.

  • Lower entry pricing
  • Price jump at 7.5mg+
  • Compounded semaglutide + tirzepatide
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →
Sponsored partner · Compounded and branded pathwaysGobyMeds

Explore the program’s treatment pathways and ask which medication type, pharmacy, enrollment requirements and recurring charges apply to your location.

Explore GobyMeds ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.

Where to Start

Embody

Injectable semaglutide — pricing varies

Injectable semaglutide only; a lead compounded-injectable option.

  • Injectable semaglutide focus
  • Standard 12-week titration
  • Direct-to-patient pharmacy shipping
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

MadeMed

Oral tirzepatide ~$229/mo

Independent compounder offering compounded oral tirzepatide.

  • Compounded oral tirzepatide
  • $167–$229 range per dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

SHED

Starts lower, $399/mo at 7.5mg+

Note: SHED's price jumps to $399/mo once you titrate to 7.5mg or higher.

  • Lower entry pricing
  • Price jump at 7.5mg+
  • Compounded semaglutide + tirzepatide
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →